Clinical Trials Logo

Filter by:
NCT ID: NCT05416333 Not yet recruiting - Clinical trials for Central Centrifugal Cicatricial Alopecia

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

(CCCA)
Start date: June 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.

NCT ID: NCT05415891 Not yet recruiting - Clinical trials for Mental Health Disorder

The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta

IMPROV
Start date: June 2022
Phase: N/A
Study type: Interventional

This project consists of a pilot trial to assess the preliminary impact of a stigma-reduction training to reduce clinic-level stigma and the You℞ Decision prescribing platform to increase HIV care providers' self-efficacy related to prescribing psychiatric medication for depression, post-traumatic stress disorder (PTSD), and bipolar disorder as well as naltrexone for alcohol use disorder (AUD).

NCT ID: NCT05411354 Not yet recruiting - Prostate Cancer Clinical Trials

Analyzing Clinical Trial Experiences of Prostate Cancer Patients

Start date: September 2024
Phase:
Study type: Observational

Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the participation or completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Prostate Cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might shed insights for the sake of future Prostate Cancer patients.

NCT ID: NCT05408910 Not yet recruiting - Cystic Fibrosis Clinical Trials

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

Start date: July 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence, abdominal pain and bowel habit changes. An alteration in the intestinal microbiome due to intestinal dysmotility, inflammation or other changes including pH changes in the intestine related to CFTR gene mutation may cause intestinal dysbiosis leading to a bacterial overgrowth in the proximal small intestine which may explain some of the findings of distension and bloating in CF. Our small pilot study aims to investigate use of the only FDA-approved antibiotic, rifaximin for a GI syndrome- IBS, to treat bloating and global GI symptoms in CF patients with bloating and distension. Our goal is to recruit patients >12 years and age/sex matched into rifaximin and placebo arms with total of 100 recruited subjects recruited.

NCT ID: NCT05403125 Not yet recruiting - Dental Caries Clinical Trials

SDF Application in Oral Cancer Patients to Prevent Dental Caries

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The Texas A & M College of Dentistry, with partner Texas Oncology-Baylor Charles A. Sammons Cancer-Center Radiation-Oncology, proposes to conduct a preliminary clinical study (NIH Stage 0) to pilot test a randomized clinical trial of the efficacy of professionally applied 38% silver diamine fluoride to prevent tooth decay in 60 patients who are being treated with radiation for life threatening head and neck cancer.

NCT ID: NCT05402384 Not yet recruiting - Clinical trials for SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, withdrawal and treatment study assessing the efficacy, safety, and tolerability of CERC-801 in subjects with SLC35A2-CDG.

NCT ID: NCT05402345 Not yet recruiting - NGLY1 Deficiency Clinical Trials

A Study of GlcNAc on Tear Production in NGLY1-CDDG

Start date: May 2024
Phase: Phase 2
Study type: Interventional

In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.

NCT ID: NCT05402332 Not yet recruiting - Clinical trials for PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation

Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG

AVTX-801
Start date: February 2024
Phase: Phase 2
Study type: Interventional

You have been asked to take part in this research study because you have been diagnosed with PGM1-CDG and are currently taking D-galactose.

NCT ID: NCT05401981 Not yet recruiting - Clinical trials for Musculoskeletal Diseases

Disjunction Between Patient Narrative and Formulaic Thinking in the Doctor

Start date: June 2022
Phase: N/A
Study type: Interventional

This study is seeking whether giving or not giving a clinician a card with talking points in the form of a checklist about the patient's story affects the patients care experience or not

NCT ID: NCT05400941 Not yet recruiting - Clinical trials for Health Care Utilization

Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This mixed methods study evaluates the effectiveness of an organizational intervention to enhance implementation of strategies to increase breast cancer survivorship symptom and risk management.